Intrahepatic cholangiocarcinoma: search for novel translational clinicopathologic and molecular biomarkers to predict early recurrence after curative surgery
肝内胆管癌:寻找新的转化临床病理学和分子生物标志物以预测根治性手术后的早期复发
基本信息
- 批准号:458302
- 负责人:
- 金额:$ 7.65万
- 依托单位:
- 依托单位国家:加拿大
- 项目类别:Studentship Programs
- 财政年份:2021
- 资助国家:加拿大
- 起止时间:2021-11-01 至 2024-11-01
- 项目状态:已结题
- 来源:
- 关键词:
项目摘要
Intrahepatic cholangiocarcinoma (iCCA) is a type of bile duct cancer located inside the liver. iCCA is the second most common cause of liver cancers and only 10% of those who are diagnosed with this cancer survive past five years. The main challenge in tr
肝内胆管癌(iCCA)是一种位于肝脏内部的胆管癌。iCCA是肝癌的第二大常见原因,只有10%的被诊断患有这种癌症的人存活了五年。TR的主要挑战
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Choi Woo Jin其他文献
Choi Woo Jin的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Choi Woo Jin', 18)}}的其他基金
Intrahepatic cholangiocarcinoma: circulating tumor DNA as a novel translational clinicopathologic and molecular biomarker
肝内胆管癌:循环肿瘤 DNA 作为新型转化临床病理学和分子生物标志物
- 批准号:
449827 - 财政年份:2020
- 资助金额:
$ 7.65万 - 项目类别:
Studentship Programs
相似海外基金
Using patient-led genetics to identify new therapeutic targets in metastatic cholangiocarcinoma
利用患者主导的遗传学来确定转移性胆管癌的新治疗靶点
- 批准号:
EP/Y028546/1 - 财政年份:2024
- 资助金额:
$ 7.65万 - 项目类别:
Fellowship
Signal to induce occupational cholangiocarcinoma and biomarker
诱发职业性胆管癌的信号和生物标志物
- 批准号:
23H03152 - 财政年份:2023
- 资助金额:
$ 7.65万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Detailed Elucidation of Cancer Immune Escape Mechanisms Focusing on Regulatory T Cells in the Microenvironment of Cholangiocarcinoma
详细阐明胆管癌微环境中调节性T细胞的癌症免疫逃逸机制
- 批准号:
23K15088 - 财政年份:2023
- 资助金额:
$ 7.65万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Mechanism-based combination therapy for cholangiocarcinoma
基于机制的胆管癌联合治疗
- 批准号:
10650049 - 财政年份:2023
- 资助金额:
$ 7.65万 - 项目类别:
SBIR CONCEPT AWARD-NANOSPONGE LINKED DCLK1 INHIBITORS FOR THE TARGETED TREATMENT OF CHOLANGIOCARCINOMA
SBIR 概念奖-纳米海绵连接的 DCLK1 抑制剂用于胆管癌的靶向治疗
- 批准号:
10975720 - 财政年份:2023
- 资助金额:
$ 7.65万 - 项目类别:
Determining the efficacy and safety of cancer chemotherapeutics for cholangiocarcinoma (CCA) using Human Precision Cut Tissue Slices (hPCTS).
使用人体精密切割组织切片 (hPCTS) 确定胆管癌 (CCA) 癌症化疗的有效性和安全性。
- 批准号:
NC/W001020/2 - 财政年份:2023
- 资助金额:
$ 7.65万 - 项目类别:
Research Grant
The Cholangiocarcinoma Conference: Molecular Drivers, Microenvironment, and Precision Medicine
胆管癌会议:分子驱动因素、微环境和精准医学
- 批准号:
10747566 - 财政年份:2023
- 资助金额:
$ 7.65万 - 项目类别:
Manipulating cholangiocarcinoma immune-phenotype in a patient derived precisioncut tumour model to improve immune checkpoint inhibition response.
在患者衍生的精确切割肿瘤模型中操纵胆管癌免疫表型,以改善免疫检查点抑制反应。
- 批准号:
2887636 - 财政年份:2023
- 资助金额:
$ 7.65万 - 项目类别:
Studentship
A new mouse model for studying the pathogenesis and immunobiology of intrahepatic cholangiocarcinoma and improving its immunotherapy
研究肝内胆管癌发病机制和免疫生物学并改进其免疫治疗的新小鼠模型
- 批准号:
10711615 - 财政年份:2023
- 资助金额:
$ 7.65万 - 项目类别:
Manipulating cholangiocarcinoma immune-phenotype in a patient derived precision-cut tumour model to improve immune checkpoint inhibition response.
在患者衍生的精确切割肿瘤模型中操纵胆管癌免疫表型,以改善免疫检查点抑制反应。
- 批准号:
NC/X001679/1 - 财政年份:2023
- 资助金额:
$ 7.65万 - 项目类别:
Training Grant